drugset / Trial / NCT01583036

An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be Assessed

NCT01583036 ↗

Phase 1 Completed 30 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelBasic science

Summary

An interaction study to assess the effect of the ezogabine/retigabine and the main metabolite NAMR on the pharmacokinetics of digoxin in healthy volunteers

Timeline

Start
2012-01-16
Primary completion
2012-04-17
Completion
2012-04-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified 0.25 mg —
Subject Ezogabine Small molecule 1200 mg —

Indications